Welcome to our dedicated page for Longeveron SEC filings (Ticker: LGVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Longeveron Inc. (NASDAQ: LGVN) SEC filings, giving investors a primary source of regulatory information about the clinical stage biotechnology company and its cellular therapy programs. Longeveron files a range of documents with the U.S. Securities and Exchange Commission, including Forms 8-K, registration statements, and other reports that describe its business, capital structure, and material events.
Recent 8-K filings have detailed topics such as public offerings of Class A common stock and warrants, an at-the-market (ATM) offering agreement, financial results for quarterly periods, changes in executive leadership and board composition, and a Nasdaq notice regarding the minimum bid price requirement for continued listing on The Nasdaq Capital Market. These filings also discuss how the company intends to use offering proceeds, including funding clinical and regulatory development of its lead mesenchymal stem cell therapy, laromestrocel (Lomecel-B), for indications like hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and pediatric dilated cardiomyopathy.
Through registration statements on Form S-1 and related amendments, Longeveron outlines the terms of securities offerings, its status as an emerging growth and smaller reporting company, and risk factors associated with its business and development plans. Investors can also review disclosures about ATM programs and material definitive agreements with placement agents.
On Stock Titan, these LGVN SEC filings are paired with AI-powered summaries that highlight key points, such as financing terms, listing compliance updates, and planned uses of capital. Users can quickly locate quarterly and annual reporting documents, transaction-related filings, and other regulatory disclosures to better understand Longeveron’s operations, funding strategy, and clinical development priorities.
Lehr Paul T reported acquisition or exercise transactions in this Form 4 filing.
Longeveron Inc. reported that General Counsel and Secretary Paul T. Lehr received an equity grant of 250,000 shares of Class A common stock as a time-based vesting Restricted Stock Unit (RSU) award. The filing notes that Lehr’s holdings, including RSUs subject to future vesting, total 588,566 shares after this grant.
Willard Stephen H reported acquisition or exercise transactions in this Form 4 filing.
Longeveron Inc. Chief Executive Officer Willard Stephen H received an equity compensation award of 500,000 shares of Class A Common Stock on May 1, 2026. The award is structured as time-based vesting Restricted Stock Units (RSUs) granted at a stated price of $0.00 per share, so it is not an open-market purchase.
Following this grant, his directly held position in Longeveron Class A Common Stock is reported as 789,727 shares, which includes RSUs that are still subject to future vesting conditions.
Longeveron Inc. reported that CTO & SVP of CMC Devin Blass acquired 250,000 shares of Class A Common Stock on a grant/award basis. The shares were awarded as time-based vesting Restricted Stock Units, and total direct holdings increased to 441,543 shares, including RSUs subject to future vesting.
Longeveron Inc. reported that Chief Medical Officer Nataliya Agafonova acquired 250,000 shares of its Class A Common Stock through an award of time-based vesting Restricted Stock Units (RSUs) on May 1, 2026 at a stated price of $0.00 per share.
After this RSU award, she directly holds 453,419 Class A shares, which include RSUs subject to future vesting. The award reflects a non-cash equity grant classified as a grant, award, or other acquisition under insider reporting rules.
Locklear Lisa reported acquisition or exercise transactions in this Form 4 filing.
Longeveron Inc. Chief Financial Officer Lisa Locklear received an award of 250,000 shares of Class A Common Stock as time-based vesting Restricted Stock Units (RSUs). The grant was recorded at $0.00 per share, reflecting a compensation award rather than an open-market purchase.
After this award, Locklear directly holds 465,686 shares of Class A Common Stock, which the footnotes state includes RSUs that are still subject to future vesting conditions.
Longeveron Inc. is soliciting proxies for its 2026 virtual Annual Meeting to be held on July 1, 2026. Key items include election of three Class II directors, a proposed increase in authorized Class A shares from 84,295,000 to 175,000,000, a possible reverse stock split in the range 1-for-2 to 1-for-20, and an amendment to expand the 2021 Incentive Award Plan.
The record date for voting is May 11, 2026, and the proxy materials, including the Annual Report for the year ended December 31, 2025, are available online at the meeting portal.
Longeveron Inc. registered 30,865,385 shares of Class A common stock for resale by certain selling stockholders. The prospectus covers (i) 6,013,384 issued shares, (ii) 22,832,770 shares issuable on conversion of Series A preferred stock, and (iii) up to 2,019,231 shares issuable on exercise of placement agent warrants.
The company will not receive proceeds from these resales, except for up to $1,312,500 if the PA Warrants are exercised for cash. Shares outstanding prior to the Private Placement were 21,783,749; fully converted/exercised outstanding would be 52,649,134 as disclosed. The registration satisfies contractual registration rights and permits the listed selling stockholders to sell shares on-market or in private transactions.
Longeveron Inc. describes changes to executive and director compensation tied to a prior cost-cutting plan. Earlier in 2026, the company temporarily reduced pay for its executive team and Board by about 25% to 50% while reviewing its cash runway and cost structure.
After closing a financing transaction reported on March 12, 2026, and determining it had the financial capacity, Longeveron repaid executives and directors the difference between their original and reduced compensation for the reduction period. In addition, the Compensation Committee approved equity awards of 250,000 restricted stock units for each executive other than the Executive Chairman and 500,000 restricted stock units for the Chief Executive Officer. These RSUs are to be granted on May 1, 2026 and vest quarterly over three years starting July 1, 2026 under the company’s Third Amended and Restated 2021 Incentive Award Plan.
Longeveron Inc. is registering 30,865,385 shares of Class A common stock for resale by existing investors, including shares already issued, shares issuable from preferred stock conversion, and shares underlying placement agent warrants. The company will not receive proceeds from these resales, but could receive up to $1.31 million if all placement agent warrants are exercised in cash.
Longeveron is a clinical-stage biotech focused on its cell therapy candidate laromestrocel (Lomecel-B®) for rare pediatric heart disease (HLHS), Alzheimer’s disease, pediatric dilated cardiomyopathy and aging-related frailty. The filing highlights a recent $15.9 million private placement, substantial doubt about the company’s ability to continue as a going concern, and Nasdaq minimum bid-price noncompliance that could lead to a reverse split or potential delisting if not cured.